The Limits of Traditional Neurodegenerative Trial Design
Dear Kenneth,
Neurodegenerative disease trials present persistent challenges—from long study durations and progressive disability to high participant burden and limited sensitivity of site-based assessments.
As digital health technologies mature, they are enabling new ways to observe disease progression through continuous, real-world data capture. At the same time, evolving regulatory frameworks are creating clearer pathways for integrating these tools into trial design.
This white paper explores:
- Why conventional trial models struggle to capture nuanced neurological change
- How digital health technologies support more continuous, patient-centric data collection
- Where decentralized and hybrid approaches can improve accessibility without compromising rigor
Download the report to explore how digital health is reshaping neurodegenerative clinical trials.
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Allucent or a third party to contact you regarding the content (by phone or email).